SHIONOGI & CO LTD - Dusseldorf Stock Exchang (SH0 DU) stock market data APIs
€12.8356
0.5(3.9%)
as of October 17, 2025
Try our APIs with
free plan!
SHIONOGI & CO LTD - Dusseldorf Stock Exchang Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for SH0.DU.
Prev. Close
12.8356
Open
13.3342
High
13.2773
Low
12.8356
52 wk Range
11.4788-15.1943
Market Cap
18 118 M
Dividends (Yield)
1.0834
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get SHIONOGI & CO LTD - Dusseldorf Stock Exchang data using free add-ons & libraries
Get SHIONOGI & CO LTD - Dusseldorf Stock Exchang Fundamental Data
SHIONOGI & CO LTD - Dusseldorf Stock Exchang Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get SHIONOGI & CO LTD - Dusseldorf Stock Exchang Earnings data
$
19.99
/mo.
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
Get SHIONOGI & CO LTD - Dusseldorf Stock Exchang End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
SHIONOGI & CO LTD - Dusseldorf Stock Exchang News
New
ViiV Healthcare announces 96-week data reaffirming Dovato is as effective as Biktarvy in maintaining virological suppression of HIV-1 with significantly less weight gain
In largest head-to-head randomized clinical trial evaluating the two medicines, Dovato (DTG/3TC) met the primary endpoint, demonstrating sustained non-inferior efficacy versus Biktarvy (BIC/FTC/TAF) i...
Gareth Morgan Named President of Qpex Biopharma, Inc.
SAN DIEGO, October 15, 2025--(BUSINESS WIRE)--Qpex Biopharma, Inc., a Shionogi Group Company (hereafter "Qpex"), announced that Gareth Morgan, MS, MBA, most recently Senior Vice President and Global H...
ViiV Healthcare’s CLARITY study shows long-acting cabotegravir more acceptable than lenacapavir injections after a single dose, with 90% preferring cabotegravir
Initial data from the CLARITY study are first to compare acceptability and tolerability of single-dose cabotegravir (CAB) and lenacapavir (LEN) long-acting injections, in 63 HIV-negative adults Sixty-...
ViiV Healthcare showcases breadth of clinical and real-world evidence at EACS and IDWeek 2025
Data from the CLARITY study will provide insights on acceptability and tolerability of single-dose cabotegravir and lenacapavir long-acting injections Four-year analysis from the OPERA cohort examines...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
